Burning Rock Biotech Limited
BNR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.02 | 0.01 | -0.00 |
| FCF Yield | 24.72% | -181.95% | -66.95% | 26.79% |
| EV / EBITDA | 110.99 | -288.36 | 27.52 | 8.90 |
| Quality | ||||
| ROIC | -2.72% | -1.87% | -2.43% | -12.73% |
| Gross Margin | 75.10% | 72.77% | 73.19% | 70.96% |
| Cash Conversion Ratio | -0.98 | 4.57 | 1.74 | – |
| Growth | ||||
| Revenue 3-Year CAGR | -1.17% | -2.89% | -2.82% | -2.89% |
| Free Cash Flow Growth | 136.97% | -88.50% | -272.45% | 145.06% |
| Safety | ||||
| Net Debt / EBITDA | 131.18 | -306.42 | 29.83 | 9.99 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.60 | 0.70 | 0.55 | 0.68 |
| Cash Conversion Cycle | 190.08 | 181.09 | 193.83 | 173.09 |